Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
|
|
Hepion Pharmaceuticals, Inc. (CTRV)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/17/2022 |
8-K
| Investor presentation |
| 05/27/2022 |
8-K
| Quarterly results |
| 01/10/2022 |
8-K
| Investor presentation |
| 09/30/2021 |
8-K
| Investor presentation |
| 09/13/2021 |
8-K
| Quarterly results |
| 01/28/2021 |
8-K
| Investor presentation |
| 10/01/2020 |
8-K
| Quarterly results |
| 06/15/2020 |
8-K
| Investor presentation |
| 05/19/2020 |
8-K
| Investor presentation |
| 03/11/2020 |
8-K
| Quarterly results |
| 02/07/2020 |
8-K
| Investor presentation |
| 12/03/2019 |
8-K
| Investor presentation|
Docs:
|
"Hepion Pharmaceuticals, Inc. Corporate Presentation",
"Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference EDISON, N.J., December 3, 2019 - Hepion Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis , announced today that management will present an update on the Company’ s business at the first annual BioTuesdays Pre-JPM Virtual Conference on Tuesday, December 10, 2019 at 11:00 a.m. Eastern Time. The presentation will be broadcast live and archived on the Company's website at https://hepionpharma.com/investors/events/. About Hepion Pharmaceuticals Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver diseas..." |
|
| 01/02/2019 |
8-K
| Investor presentation |
| 05/28/2015 |
8-K
| Investor presentation |
|
|